Healinno Tech Recognized Among CVINFO's 2024 Top 10 Investment Cases in China's Medical Device Industry

Healinno Tech today announced that it has been selected for CVINFO's "2024 Top 10 Investment Cases in China's Medical Device Industry", one of the annual awards recognizing outstanding investment cases in China's healthcare and health services sector.

This recognition not only acknowledges Healinno Tech's outstanding achievements in the medical device industry, but also affirms the company's strong investment value and long-term growth potential.

Healinno Tech extends its sincere appreciation to its shareholders for their continued trust and support. The company's investors include Shunwei Capital, Yizhuang Capital, Lilly Asia Ventures (LAV), ZHONGHAI Investment, Vivo Capital, and Lenovo Capital & Incubator Group (LCIG), listed in chronological order of investment. Their support has provided not only strong financial backing but also valuable resources for technology innovation, product development, and market expansion.

Healinno Tech CEO Stanley Shi commented:

"We are honored to be recognized among CVINFO's Top 10 Investment Cases. This achievement would not have been possible without the unwavering trust and support of our shareholders. Looking ahead, we will continue to focus on the development and commercialization of innovative medical technologies, delivering better treatment solutions for patients while creating long-term value for our investors."

This award reflects Healinno Tech's leadership in medical device innovation while further demonstrating the strong confidence the capital market continues to place in the company's future.

We sincerely thank all of our shareholders for their continued confidence and support, and we look forward to achieving continued growth and success together with all of our partners.

About CVINFO

nformation and data services, offering professional investment intelligence, industry research, and market analysis to investors, enterprises, and government organizations. Its annual rankings and research reports are widely recognized as authoritative references within China's private equity and venture capital industry.